The Effect of Kallikrein on Sperm Motility in Asthenozoospermia / 대한비뇨기과학회지

ABSTRACT

Kallikrein preparation have already been accepted as therapeutic for male infertility. Especially oral Kallikrein therapy exerted a favorable effect on sperm motility in oligozoospermia and asthenozoospermia. We have carried out a Similar clinical examination of the effect of kallikrein taken orally 60 KU per day for 3-9 months, on the qualitative increase of motile spermatozoa in normogonadotropic infertile males with l0 idiopathic oligozoospermia (less than 20 x 10(6)/ml), 10 idiopathic asthenozoospermia (less then 20% of sperm motility) and 8 idiopathic asthenozoospermia entered the study as control placebo treatment group. Number of spermatozoa increased more than 30% of basic levels (over 30 x 10(6)/ml) in the 2 patient(20 %) and pregnancy occurred in the l patient (10%) out of the 10 patients with idiopathic oligozoospermia after the kallikrein therapy. In these 2 patients responded, the sperm concentration changed from 15.4 x 10(6)ml to 43.0 x 10(6)/ml. Sperm motility improved more than 20% in the 3 patients (30%) and pregnancy occurred in the 2 patients (20%) out of the 10 idiopathic asthenozoospermia after the therapy. In these 3 patients improved, the sperm motility changed from l3.2% to 43.5%. Sperm motility was increased only 1 patient (12.5%) out of the 8 placebo treatment control group and no pregnancy occurred to a side effect of kallikrein.